Akebia Therapeut Stock Price, News & Analysis

Akebia Therapeutics (Nasdaq: AKBA) presented a post-hoc win-odds analysis from the Phase 3 INNO2VATE dialysis trials at ASN Kidney Week on Nov 6, 2025 showing a statistically more favorable composite of all-cause mortality and hospitalization for patients receiving Vafseo (vadadustat) versus darbepoetin alfa. The analysis reported an inverted win-odds of 0.93 (95% CI 0.87–0.99; P=0.03) on study and 0.86 (95% CI 0.81–0.95; P<0.0001) on treatment plus 28 days. Vafseo is approved for dialysis-dependent CKD anemia and available in the U.S. since January 2025. The company noted ongoing real-world trials including VOICE to further measure mortality and hospitalizations.

Akebia Therapeutics (Nasdaq: AKBA) announced that CEO John P. Butler and Chief Financial and Chief Business Officer Erik Ostrowski will present at two investor conferences in November 2025. They will appear at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10, 2025 with a fireside chat at 3:00 PM EST, and at the Jefferies Global Healthcare Conference in London on November 17, 2025 with a fireside chat at 12:00 PM GMT.

A webcast of each presentation will be available through the Investors section of Akebia’s website at https://ir.akebia.com following the conferences.

Akebia Therapeutics (Nasdaq: AKBA) granted stock options to three newly hired employees on October 31, 2025 as inducement awards under Nasdaq Listing Rule 5635(c)(4). An aggregate of 51,825 options were issued with an exercise price of $2.21 per share, equal to the closing price on the grant date.

The options vest over four years (25% at the first anniversary, then quarterly for the remaining 75%), have a 10-year term, and are subject to Akebia’s inducement award program and stock option agreement, and to continued service requirements.

Akebia Therapeutics (Nasdaq: AKBA) will release its third quarter 2025 financial results for the period ended September 30, 2025 on Monday, November 10, 2025 prior to market open.

The company will host a conference call on November 10, 2025 at 8:00 a.m. EST to discuss results and recent business highlights. Investors are asked to register for dial‑in details and to dial in 15 minutes early to avoid delays. A live webcast and an online archive will be available in the Investors section at https://ir.akebia.com/.

Akebia Therapeutics (Nasdaq: AKBA) announced it does not expect to initiate the VALOR clinical trial for vadadustat in late-stage chronic kidney disease patients not on dialysis after a Type C meeting with the U.S. FDA on Oct. 28, 2025. Akebia said it did not reach alignment with the FDA on trial design and believes a regulatory pathway would require a significantly larger patient population than proposed, adding materially more time and cost.

The company does not expect to pursue a broad non-dialysis CKD label for Vafseo, but said FDA feedback indicated potential alignment on smaller CKD subgroups. Vafseo is approved in the U.S. for adults on dialysis; U.S. nephrologists began prescribing in January 2025.

Akebia Therapeutics (Nasdaq: AKBA) will present five scientific items at ASN Kidney Week 2025 in Houston, Nov 5-9, 2025, and staff the company booth #903.

Highlights include an oral win‑odds analysis of all‑cause mortality and hospitalization from the global Phase 3 INNO2VATE trials (presenter: Glenn M. Chertow, MD) on Nov 6, 2025, 4:30–6:00 PM CT, Room 351D, and four Akebia‑supported posters on Nov 6–7 covering model‑based starting dose recommendations for Vafseo (vadadustat), dosing consistency vs darbepoetin, and two ongoing real‑world randomized studies (VOICE and VOCAL) assessing three‑times‑weekly vadadustat in dialysis patients. Vafseo is approved in the U.S. for anemia in adults on dialysis ≥3 months.

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to seven new employees as employment inducement awards. The options total 204,163 shares with an exercise price of $2.73 per share, matching the closing price on September 30, 2025.

The options feature a four-year vesting schedule with 25% vesting after one year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia. The grants were made under Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has awarded stock options to two new employees as employment inducement grants. The options total 95,100 shares of common stock with an exercise price of $3.14 per share, matching the closing price on August 29, 2025.

The options feature a four-year vesting schedule, with 25% vesting after one year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and are governed by Akebia's inducement award program and stock option agreements.

Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has announced its participation in two upcoming investor conferences in September 2025. The company's executives will present at the Wells Fargo Healthcare Conference in Boston (September 3-5) and the H.C. Wainwright 27th Annual Global Investment Conference in New York (September 8-10).

Chief Financial and Chief Business Officer Erik Ostrowski and Chief Commercial Officer Nik Grund will lead both presentations. The Wells Fargo presentation is scheduled for September 4 at 8:00 AM EDT, while the H.C. Wainwright fireside chat will take place on September 8 at 12:00 PM EDT. Webcasts will be available through Akebia's investor relations website.